Cargando…

Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jilong, Zheng, Zhinan, Lei, Jia, Cao, Yuxin, Li, Qiyun, Zheng, Zhi, Chen, Chuanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321753/ https://www.ncbi.nlm.nih.gov/pubmed/34335707 http://dx.doi.org/10.1155/2021/5589342

Ejemplares similares

EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target
por: Lin, Zhuangling, et al.
Publicado: (2023)

An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
por: Li, Ziqi, et al.
Publicado: (2020)

EZH2: novel therapeutic target for human cancer
por: Li, Long-Yuan
Publicado: (2014)

PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
por: Jiang, Yanli, et al.
Publicado: (2019)

HFD-induced TRAF6 upregulation promotes liver cholesterol accumulation and fatty liver development via EZH2-mediated miR-429/PPARα axis
por: Zhang, Zhi, et al.
Publicado: (2021)

PPARα: A potential therapeutic target of cholestasis
por: Ye, Xiaoyin, et al.
Publicado: (2022)

Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases
por: Li, Tingting, et al.
Publicado: (2021)

EZH2 in Bladder Cancer, a Promising Therapeutic Target
por: Martínez-Fernández, Mónica, et al.
Publicado: (2015)

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018)

PPARδ, a Potential Therapeutic Target for Heart Disease
por: Yang, Qinglin, et al.
Publicado: (2018)

Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts
por: Zhu, Wen-Si, et al.
Publicado: (2016)

Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis
por: Zheng, Qian-Wen, et al.
Publicado: (2021)

Regulation of TRAIL expression by PRAME and EZH2 as potential therapeutic target against solid tumors
por: Mello, Barbara P, et al.
Publicado: (2013)

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
por: Uebel, Anne, et al.
Publicado: (2023)

The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer
por: Wang, Jieyu, et al.
Publicado: (2023)

Potential Therapeutic Targets for PPARγ after Spinal Cord Injury
por: McTigue, Dana M.
Publicado: (2008)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine
por: Barazeghi, Elham, et al.
Publicado: (2021)

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?
por: Ding, Shu, et al.
Publicado: (2022)

lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
por: Wozniak, Michal, et al.
Publicado: (2023)

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
por: Wang, Bohan, et al.
Publicado: (2023)

Neuroprotective Potential of Gentongping in Rat Model of Cervical Spondylotic Radiculopathy Targeting PPAR-γ Pathway
por: Sun, Wen, et al.
Publicado: (2017)

PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
por: Monroy-Ramirez, Hugo Christian, et al.
Publicado: (2021)

EZH2 as a Potential Target for NAFLD Therapy
por: Lim, Hyun Jung, et al.
Publicado: (2020)

Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013)

Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: A novel pathway of carcinogenesis
por: Rojanasakul, Yon
Publicado: (2013)

Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
por: Reich, D, et al.
Publicado: (2018)

Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis
por: Zheng, Xiangrong, et al.
Publicado: (2017)

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target
por: Li, Hua, et al.
Publicado: (2013)

The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
por: Li, Zhongwu, et al.
Publicado: (2013)

Targeting EZH2 as a novel therapeutic strategy for sorafenib‐resistant thyroid carcinoma
por: Wang, Zhengshi, et al.
Publicado: (2019)

IL-33/ST2 Axis: A Potential Therapeutic Target in Neurodegenerative Diseases
por: Jia, Zexi, et al.
Publicado: (2023)

PPAR-γ: Therapeutic Potential for Multiple Sclerosis
por: Drew, Paul D., et al.
Publicado: (2008)

Therapeutic Potential of PPARγ Activation in Stroke
por: Vemuganti, Raghu
Publicado: (2008)

Impact and Therapeutic Potential of PPARs in Alzheimer's Disease
por: Heneka, Michael T, et al.
Publicado: (2011)

Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
por: Basilotta, Rossella, et al.
Publicado: (2022)

PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
por: Corona, Juan Carlos, et al.
Publicado: (2014)

PPARγ as a Novel Therapeutic Target in Lung Cancer
por: Reddy, Aravind T., et al.
Publicado: (2016)

Functional and therapeutic significance of EZH2 in urological cancers
por: Liu, Xiaobing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ajrk89a687g7e62p34p0lvkfsu